Here’s what you should know:
1. The blood test can identify if IBS or IBD is present in a patient’s blood profile with greater than 90 percent accuracy.
2. The test gives physicians information to distinguish between Crohn’s disease and ulcerative colitis.
3. This is the second test IQuity has brought to market to date. The company is releasing a Fibromyalgia test before the end of 2017.
IQuity CEO Chase Spurlock PhD said in a release, “The process of diagnosing IBS and IBD can be time-consuming and physically and emotionally draining for patients. With IsolateIBS-IBD, we’re providing a potent new tool to aid physicians as they work with patients to achieve an accurate, early diagnosis. We want to help eliminate uncertainty and give physicians and patients information that they can trust, leading to an early and effective treatment.”
More articles on gastroenterology:
GI leader to know: Dr. Donald Gerhardt of Gastrointestinal Associates
Stock market week-in-review for 5 large GI companies — Nov. 13-17
Outpost Medicine pivots to ‘new class of oral therapy’ for IBS — 3 insights
